Skip to main navigation
Skip to search
Skip to main content
Icahn School of Medicine at Mount Sinai Home
Help & FAQ
Home
Profiles
Research units
Publications & Research Outputs
Press/Media
Search by expertise, name or affiliation
Bimekizumab for the treatment of psoriatic disease
Nicola E. Natsis,
Alice B. Gottlieb
Research output
:
Contribution to journal
›
Article
›
peer-review
19
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Bimekizumab for the treatment of psoriatic disease'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Psoriatic Arthritis
100%
Bimekizumab
100%
Phase III Clinical Trial
28%
Interleukin-17 (IL-17)
28%
Phase II Study
28%
IL-17F
28%
Adverse Events
14%
Clinical Trials
14%
Physical Burden
14%
Response to Therapy
14%
Expert Opinion
14%
Tolerability
14%
Common Disease
14%
Phase II Clinical Trial
14%
Significant Disease
14%
Area Cover
14%
New Biologics
14%
Symptom Improvement
14%
FDA-approved Drugs
14%
Associated Risk
14%
Disease Resolution
14%
Disease Improvement
14%
Bispecific Targeting
14%
Emotional Burden
14%
Pharmacology, Toxicology and Pharmaceutical Science
Disease
100%
Bimekizumab
100%
Clinical Trial
42%
Biological Product
42%
Psoriasis
42%
Psoriatic Arthritis
42%
Adverse Event
14%
Side Effect
14%
Tolerability
14%